Ab Initio Leads Oral Formulation of World-First Radiation Protectant

We’re proud to announce a key milestone in the development of SAi001 — the world’s first multi-organ radiation protectant — in partnership with the University of Adelaide and SAiGENCI.

With support from the Australian Economic Accelerator (AEA) Seed Grant, Ab Initio Pharma has successfully developed a new oral dosage form incorporating advanced formulation strategies which allow for scalable manufacturing while enabling targeted, controlled delivery — a critical step toward clinical application.

The project highlights our core capability: translating cutting-edge science into robust, GMP-compatible dosage forms that are ready for real-world development.

We’re now progressing toward the next phase with our collaborators, supporting a pathway to first-in-human studies and future deployment across oncology, defence, and space medicine.

Ab Initio Pharma — experts in advanced oral drug delivery.

Extensive pre-clinical studies of SAi001 have demonstrated promising results, with potential uses for the space, defence, mining industries, and for cancer treatment. Ab Intitio has now developed a scalable oral dosage form